FDA Inspection
Frontida BioPharm IncFrontida BioPharm Inc – FDA Inspection, Mar 31, 2017
Record Details
This FDA Inspection record concerns Frontida BioPharm Inc, with an inspection on March 31, 2017, issued by the Center for Drug Evaluation and Research, covering drugs.
View Company Profile
ID · ecd75cf3-3eb9-47eb-a2f2-38adbdb18510
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1007832
- FDA center
- Human Drugs
- Project area
- Drug Quality Assurance
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 211.192Investigations of discrepancies, failures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Frontida BioPharm Inc
14| Date | Classification | Office | Project area |
|---|---|---|---|
| April 2, 2026 | Not classified | Philadelphia District Office | |
| July 22, 2025 | NAI | Center for Tobacco Products | Tobacco Post-Market Activities |
| July 22, 2025 | NAI | Center for Tobacco Products | Tobacco Post-Market Activities |
| December 7, 2023 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| July 19, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Frontida BioPharm Inc
- FDA Inspection 1316756 - 2026-04-02
- FDA Inspection 1280570 - 2025-07-22
- FDA Inspection 1279864 - 2025-07-22
- FDA Inspection 1226606 - 2023-12-07
- FDA Inspection 1097023 - 2019-07-19
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.